AI 업계의 약세 종목: 레커션 제약과 피버르의 회복 가능성 분석
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
두 주식 모두 단기적인 방향성을 제시하는 구체적인 뉴스가 없어, 중립적인 입장을 유지하는 것이 합리적입니다. 장기적인 회복 가능성을 고려하되, 단기적인 방향성은 불분명합니다.
핵심 요약
레커션 제약은 AI 기반 약물 개발에 집중하지만 아직 승인된 제품이 없습니다.
핵심요약
- 레커션 제약은 AI 기반 알고리즘을 사용하지만, 승인된 제품이나 후기 임상 연구가 없습니다
- 피버르는 최근 어려움을 겪고 있지만, 장기적인 회복 가능성을 고려할 만한 종목입니다
- 두 회사 모두 투자자들이 주목할 만한 잠재력이 있습니다
도입
이 기사는 AI 산업 내 약세 종목에 대한 분석을 제공하며, 장기적인 회복 가능성을 고려하는 투자자들에게 유용한 정보를 제시합니다. 특히 레커션 제약과 피버르와 같은 기업이 어떻게 AI 기술을 활용하여 시장 경쟁력을 강화할 수 있는지 살펴보는 것이 중요합니다.
본문 1: AI 기반 약물 개발의 미래
레커션 제약은 AI 기반 알고리즘을 사용하여 약물 개발 과정을 혁신하고자 합니다. 그러나 아직 승인된 제품이나 후기 임상 연구가 없기 때문에, 기술의 실용성이 입증되기 전까지는 투자자에게 불확실성이 존재합니다. 만약 레커션 제약이 성공적으로 약물을 개발한다면, 이는 산업 전체에 큰 영향을 미칠 수 있습니다. 특히 기존의 약물 개발 과정을 개선할 수 있는 잠재력이 있습니다.
본문 2: 피버르의 시장 전략
피버르는 최근 어려움을 겪고 있지만, 장기적인 회복 가능성을 고려할 만한 종목입니다. 피버르는 플랫폼을 통해 프리랜서와 고객을 연결하는 서비스를 제공하며, 이는 디지털 경제의 성장에 따라 수요가 증가할 가능성이 있습니다. 그러나 경쟁이 치열한 시장 환경에서 성공하기 위해서는 지속적인 혁신이 필요합니다. 피버르가 어떻게 시장 경쟁력을 강화할 수 있을지 주목해야 합니다.
본문 3: 투자 전망
레커션 제약과 피버르 모두 장기적인 회복 가능성을 고려할 만한 종목입니다. 그러나 투자자에게는 기술의 실용성과 시장 환경에 대한 깊은 분석이 필요합니다. 특히 AI 기술의 발전과 디지털 경제의 성장이 어떻게 두 기업의 성장 가능성에 영향을 미칠지 예측하는 것이 중요합니다.
결론
레커션 제약과 피버르는 AI 산업 내 약세 종목이지만, 장기적인 회복 가능성을 고려할 만한 잠재력이 있습니다. 투자자는 기술의 실용성과 시장 환경에 대한 분석을 통해 투자의 적절성을 판단해야 합니다. 향후 두 기업의 발전 동향을 주목해야 합니다.
Original Article
2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying
One way to capitalize on the artificial intelligence (AI) industry is to invest in companies that could benefit from the technology, have lost significant market value in recent years, and could bounce back to deliver solid returns over the long run. Do Recursion Pharmaceuticals ( RXRX +3.41% ) and Fiverr ( FVRR 4.11% ) belong to that group? Both companies are facing headwinds that have sent their stock prices down significantly, but if they can recover, buying their shares on the dip may be an excellent move. Let's find out what's going on with Recursion Pharmaceuticals and Fiverr and why contrarian investors may want to keep an eye on them.
Recursion Pharmaceuticals is an AI-focused biotech company looking to revolutionize how we develop drugs. It's arguably long overdue. Despite technological advances, the cost and time required to develop novel medicines have increased, a phenomenon known as Eroom's law. Perhaps AI will finally help change that. Recursion Pharmaceuticals uses an AI-powered algorithm that continuously runs virtual experiments to select which candidates to send to clinical trials.
Most new compounds that enter the clinic never make it to market, but the biotech hopes to improve its success rate in this area compared to the industry average, thanks to its differentiated approach. If it can, the company will launch drugs much faster than its peers while generating stronger margins and profits. However, despite Recursion Pharmaceuticals' ambitious goals, the company has yet to produce much tangible evidence that its strategy can work. It has no approved products, and none in late-stage studies either.
Further, pharmaceutical leaders with much deeper pockets than Recursion Pharmaceuticals are recognizing the potential of AI in drug development and are working to incorporate the technology into their day-to-day operations. Some have already done so. Eli Lilly ( LLY +0.91% ) built the industry's most powerful supercomputer. Recursion Pharmaceuticals could still find success if it makes meaningful clinical and regulatory progress over the next few years.
Some of the company's candidates look rather promising. For instance, the company is developing REC-4881 for the treatment of f amilial adenomatous polyposis (FAP). This rare disease leads to precancerous gastrointestinal polyps forming in the colon and rectum, and usually eventually leads to patients getting colorectal cancer . There is no approved medicine in this niche, but REC-4881 has shown promise in clinical trials by significantly reducing polyp burden.
If this candidate succeeds and earns approval, it will help validate Recursion Pharmaceuticals' approach and probably send its share price soaring. So, there is ample upside potential here, but there is also plenty of risk, as Recursion might run into clinical or regulatory roadblocks that could sink its stock price further. The stock isn't for risk-averse investors, but those with a strong tolerance for volatility may consider it.
Fiverr is a platform that connects freelancers with clients who need their services. The company initially got a bit of a boost thanks to AI. Smaller businesses that need AI services but don't have the means to hire entire teams of PhD experts have turned to Fiverr to find qualified freelancers who can get some of the work done for less. However, Fiverr is facing several headwinds. The company's revenue is moving in the wrong direction, while active buyers on its platform are also declining.
Can Fiverr successfully bounce back from recent woes? The good news is that Fiverr is implementing various initiatives that management believes will improve its financial results and prospects. For instance, the company is increasingly becoming a platform where clients go to for complex projects. Note that this is a significant shift in strategy. Fiverr's name originally came from the fact that freelance services on its platform had a starting price of $5. It was sought after for quick, relatively easy, one-off gigs. Now, projects worth $1,000 and more are growing rapidly on the platform, and management is doubling down.
Fiverr hopes that these and other initiatives will help boost engagement and spend per buyer on the platform. It's also worth noting that despite its revenue moving south, Fiverr's net income improved during the first period. Earnings per share were $0.23, significantly higher than the $0.02 reported in the year-ago period. Fiverr plans on maintaining this disciplined approach even as it seeks to improve its business.
Even so, there are significant risks ahead. Despite the company's efforts, revenue and active buyers may continue declining. Further, although AI-related projects on its platform have sometimes helped, AI has also hurt the freelance landscape, as businesses increasingly rely on AI to complete projects that would previously have required freelancers. That's probably why Fiverr is focusing on more complex jobs that AI can't easily do, and if the company's new strategy works, its share price could climb significantly over the next five years. Contrarian investors may consider initiating a small position in the stock.